Monday, October 7, 2019
Vivus up 4% on advancement of Qsymia in Europe
Thinly traded nano cap VIVUS (VVUS +4.3%) is up, albeit on very light volume, on the heels of its announcement that
that its marketing application in Europe seeking approval of Qsymia
(phentermine and topiramate extended-release) has been accepted for
review by lead member state Sweden. If approved, the weight loss med
will be authorized for sale throughout the EU as early as H2 2020 under
its decentralized procedure.
The FDA approved it in July 2012.
https://seekingalpha.com/news/3504235-vivus-4-percent-advancement-qsymia-europeUCB challenges Roche patent covering IL-17-targeting antibodies
Based on a petition from UCB S.A. (OTCPK:UCBJF), the USPTO’s Patent Trial and Appeal Board (PTAB) will review the validity of Roche (OTCQX:RHHBY +0.4%) unit Genentech’s U.S. Patent No. 10,011,654 covering antibodies that target interleukin-17A, a proinflammatory cytokine.
The patent is part of a lawsuit that Genentech filed against Eli Lilly (LLY +0.2%)
last year claiming its entitlement to royalties on arthritis med Taltz
(ixekizumab), an IL-17A inhibitor. Lilly disagrees and has also filed a
petition with the PTAB.
https://seekingalpha.com/news/3504267-ucb-challenges-roche-patent-covering-ilminus-17-targeting-antibodiesBristol-Myers sues Dr. Reddy’s to block generic Sprycel
Bristol-Myers Squibb (BMY +0.7%) has filed a lawsuit in a New Jersey court against Dr. Reddy’s Laboratories (RDY -0.6%)
in an attempt to block the commercial entry of the latter’s generic
version of leukemia med Sprycel (dasatinib). It claims that RDY’s
product infringes on two patents that expire in 2025 and 2026,
respectively.
Sprycel accounted for 8.5% ($1,003M) of BMY’s H1 product sales of $11,744M.
https://seekingalpha.com/news/3504307-bristol-myers-sues-dr-reddys-block-generic-sprycel
Subscribe to:
Posts (Atom)